Thymalin: What the Evidence Actually Shows

Thymalin is sold as a thymic peptide "bioregulator," and its name invites an obvious mix-up this article is written specifically to clear up: it is not a variant of Thymosin Alpha-1 or Thymosin Beta-4, both already covered in this site's own separate evidence reviews. Thymalin is a chemically and historically distinct product, from an independent Soviet research program, with its own separate — and, this article found, genuinely larger — published literature.

What it actually is, and why the "Thym-" name is a real source of confusion

Thymalin is a polypeptide complex — a mixture of low-molecular-weight peptides extracted directly from calf thymus tissue, not a single defined synthetic sequence the way Epitalon or Pinealon are. It was developed by Vladimir Khavinson and Vyacheslav Morozov at the Military Medical Academy in Leningrad (now St. Petersburg) starting in the 1970s, as part of a Soviet research program studying thymus-derived extracts as immune-restorative therapy. This is a genuinely separate discovery lineage from Thymosin Alpha-1 and Thymosin Beta-4, both of which trace to a parallel but independent American research program from roughly the same era (Allan Goldstein's group, which isolated "Thymosin Fraction 5" from calf thymus and later identified Thymosin Alpha-1 as its most active component). Two research groups, on opposite sides of the Cold War, extracting immune-modulating material from the same organ around the same time, arriving at different products with different chemistries and different regulatory histories — a real historical parallel, not a shared lineage, and the source of the name-adjacent confusion this article exists to resolve rather than repeat. A 2020 mechanistic paper from Thymalin's own originating lab states its identity directly: "Thymalin is a polypeptide complex isolated from the thymus and regulating the functions of the immune system²."

The published literature, sized precisely — larger than this site's other Khavinson-lab compounds

A live PubMed search for "Thymalin" returns 293 total indexed papers — a genuinely large literature, more than double Epitalon's own 142-paper record covered in this site's separate evidence review, and more than 13 times the size of Pinealon's 22-paper record. A live author-field search for "Khavinson" combined with "Thymalin" returns 89 of those 293 papers, about 30% — less concentrated in the originating lab's own output than Epitalon's 63%, consistent with genuinely broader, more independent adoption across Russian clinical specialties (dentistry, tuberculosis treatment, otolaryngology, and recently COVID-19) rather than a single lab publishing about its own product repeatedly.

The human longevity claim — real numbers, from an uncontrolled comparison

The single most substantial, and most directly relevant to the "geroprotective"/longevity marketing built on top of Thymalin, is a 2003 paper from Thymalin's own co-inventors: a clinical comparison of 266 elderly and older persons, observed over 6 to 8 years, given Thymalin, Epithalamin (the pineal-extract precursor related to Epitalon), both combined, or neither¹. The reported results are real and specific: acute respiratory disease incidence fell 2.0-2.4-fold; and mortality during the observation period fell 2.0-2.1-fold in the Thymalin-only group, 1.6-1.8-fold in the Epithalamin-only group, and 2.5-fold in the group given both — with a separate cohort given both bioregulators annually for six straight years showing a 4.1-fold mortality reduction versus control¹. Those numbers deserve to be read with the same precision this corpus's Epitalon article applies to that same lab's earlier human report: this is a real, published clinical comparison with a genuinely large cohort (266 patients) and a genuinely long observation window (6-8 years) — and it is not described as randomized or blinded anywhere in its own abstract, and it comes from the same two researchers who developed both products being studied. A real, substantial finding, reported at the study-design strength it actually has rather than the strength a "prolongs human life" headline implies.

A real, current, and different kind of evidence: COVID-19

Separately from the longevity claim above, a more recent and mechanistically distinct body of work emerged around COVID-19, worth reporting because it is current and because it tests a specific, checkable biological claim rather than a broad geroprotective one. A 2020 laboratory study from Thymalin's own originating lab found that Thymalin reduced expression of CD44 and CD117 (early hematopoietic stem cell markers) by 2-3 times while increasing expression of CD28 (a marker of mature T lymphocytes) by 6.8-fold in human cell samples — evidence, the authors argue, that Thymalin stimulates differentiation of blood stem cells into the specific mature T-lymphocyte population that becomes depleted in severe COVID-19². A follow-up 2021 paper reports a real hospital-based human comparison: patients receiving Thymalin added to standard COVID-19 therapy showed accelerated normalization of interleukin-6, C-reactive protein, and D-dimer — real, quantified inflammatory and clotting-risk markers — compared with patients on standard therapy alone³. As with the longevity study above, this is real human clinical data, not described as randomized in the paper's own reporting, again sourced substantially to the compound's own originating research group.

The regulatory picture

Thymalin has no FDA-approved product in the United States. A live check of DailyMed's structured-product-label search returns zero results, and openFDA's Drugs@FDA and FAERS databases both return no matches. A live, full-text search of FDA's current 503A Bulks List and its companion significant-safety-risks page found no mention of "thymalin" in either document — no U.S. compounding-review status exists at all. Separately, this article's own reading of Thymalin's published literature found it repeatedly described, in the plain language of its own peer-reviewed papers, as "the peptide drug thymus thymalin²" and "the drug Thymalin" — language consistent with genuine, ongoing registered clinical use in Russia. This article could not independently verify Russia's own drug-registry status through a live check, since that falls outside the English-language, PubMed-indexed, and U.S. federal database sources this review's method relies on, and states that limitation directly rather than asserting a specific registration date sourced only to a vendor page.

What this means if you're considering it

None of the 31 providers this site's own reviews cover sell Thymalin — this site's own identity-layer research confirms it is not tagged to any reviewed seller. Thymalin sits in a genuinely distinct place among this site's Khavinson-lab bioregulator coverage: a larger, less single-lab-concentrated published literature than either Epitalon or Pinealon, a real 266-patient, multi-year human mortality comparison that is genuinely substantial in size but not randomized or blinded, and a real, current, mechanistically specific body of COVID-19 research adding recent human data outside the longevity claim entirely. It is not the same product as this site's separately reviewed Thymosin Alpha-1 or Thymosin Beta-4, despite the name-adjacent confusion — different chemistry, different discovery history, different regulatory record. Our reconstitution calculator does the vial-to-syringe arithmetic on the numbers you enter for the lyophilized injectable vial actually sold under this name; it cannot confirm a vial's contents match the material used in any of the studies discussed above. Readers researching this site's other thymic-peptide coverage can find our Thymosin Alpha-1 evidence review (approved in 35+ countries as Zadaxin, never in the U.S.) and our Thymosin Beta-4 evidence review (a genuinely different molecule from the TB-500 fragment this site also covers) here.